| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.93.5.857 |
| P8608 | Fatcat ID | release_awssdqpzuna43owdi37yommtfu |
| P698 | PubMed publication ID | 8598075 |
| P2093 | author name string | Collen D | |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombolysis | Q1931577 |
| P304 | page(s) | 857-865 | |
| P577 | publication date | 1996-03-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Fibrin-selective thrombolytic therapy for acute myocardial infarction | |
| P478 | volume | 93 |
| Q47373625 | Acoustic determination of performance and equivalence of plasminogen activators |
| Q34114460 | Advances in the pharmacology of acute coronary syndrome. Platelet inhibition |
| Q36179802 | Alteplase |
| Q40207781 | Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors |
| Q41279674 | Cardiology. Acute coronary syndromes: Virchow's triad revisited |
| Q47422070 | Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase |
| Q48862997 | Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine |
| Q30500397 | Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent |
| Q35869764 | HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression |
| Q30305538 | Management of Acute Ischemic Coronary Syndromes: The Present and Future |
| Q71703391 | Modern management of acute myocardial infarction |
| Q34013442 | Molecular basis of thrombolytic therapy |
| Q34534023 | NANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY. |
| Q33663282 | New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate |
| Q47616364 | One-step thickness shear mode acoustic assay for plasminogen activators |
| Q34075199 | Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction |
| Q73621576 | Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes |
| Q73084825 | Staphylokinase requires NH2-terminal proteolysis for plasminogen activation |
| Q41720185 | Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent |
| Q92277771 | Structural Biology and Protein Engineering of Thrombolytics |
| Q33944248 | Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation |
| Q33714889 | Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis |
| Q35624598 | The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase |
| Q43665391 | Toxicology studies with recombinant staphylokinase and with SY 161-P5, a polyethylene glycol-derivatized cysteine-substitution mutant. |
| Q41589794 | Unmet therapeutic needs in the management of acute ischemia |
| Q74521066 | [Optimization of thrombolytic treatment in acute myocardial infarct: the role of new fibrinoselective drugs and their combination with new antithrombotics] |
Search more.